1.45
+20.83%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medivir
Its shares trade on Nasdaq Stockholm under the ticker MVIR.ST. It has been listed since 29 February 1996. In the fiscal year to 31 December 2025, it reported revenue of SEK 8.5m and a net loss of SEK 94.4m. At that date it held total assets of SEK 306.4m and shareholders' equity of SEK 264.5m.
Medivir AB engages in the development of pharmaceuticals products. The company is headquartered in Huddinge, Stockholm. The firm specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The firm's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Feb 1996
- Employees
- 9
- Website
- medivir.se ↗
Leadership
Pay as last reported
- Prof. Uli HacksellIndependent Chairman of the Board, since 2018SEK 690,000
- Mr. Jens LindbergChief Executive OfficerSEK 7.2m
- Mr. Magnus ChristensenChief Financial OfficerSEK 221,000
- Mr. Fredrik OebergChief Scientific Officer
- Ms. Malene JensenVice President - Clinical Development
- Ms. Pia BaumannChief Medical Officer
- Mr. Yilmaz MahshidDirector, since 2020SEK 260,000
- Dr. Lennart HanssonIndependent DirectorSEK 260,000
- Dr. Angelica LoskogIndependent DirectorSEK 260,000
- Ms. Anna TornerIndependent DirectorSEK 260,000
- Prof. Bengt WestermarkIndependent DirectorSEK 260,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 8
- Social
- 35
- Governance
- 28
- Women in the workforce
- 60%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medivir AB has a focused research pipeline with multiple clinical-stage projects.
- The company specializes in protease inhibitor design and nucleoside science for cancer therapies.
- Medivir employs 9 full-time employees with a headquarters in Huddinge, Sweden.
Weaknesses
- The company has a small workforce of only 9 employees.
- Medivir's clinical pipeline includes only a few projects with limited development stages.
- The firm's operations are concentrated in a single location with no mention of global presence.
Opportunities
- Collaboration with other institutions on additional research projects offers potential growth.
- The development of therapies for cancers with unmet medical need could attract significant market interest.
- Expanding the clinical pipeline beyond current projects may enhance business prospects.
Threats
- The small employee count may limit the company's ability to scale operations rapidly.
- Clinical trials in early phases (I/II) carry high risk of failure or delays.
- Competition in the biotechnology sector for cancer therapies is intense.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.